| NERVGEN PHARMA CORP. |
| Kanada |
| Gesundheit |
| CA64082X2032 / A2QP3D |
| 9UA (Frankfurt) |
| FRA:9UA, ETR:9UA, 9UA:GR |
| - |
| https://nervgen.com/ |
|
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics to enable nervous system repair following trauma and disease. Its lead candidate, NVG-291, a subcutaneously administe..
>Volltext.. |
| 255.16 Mio. EUR |
| 248.21 Mio. EUR |
| - |
| -15.81 Mio. EUR |
| -16.06 Mio. EUR |
| -0.22 EUR |
| 0.02 Mio. EUR |
| 7.07 Mio. EUR |
| -10.43 Mio. EUR |
| 0.71 |
| - |
| 0.86% |
| - |
| - |
| - |
| - |
| NERVGEN |
| 03.04.26 |
|